Format

Send to

Choose Destination
See comment in PubMed Commons below

Bupropion, mirtazapine, and reboxetine in the treatment of depression: Executive summary of final report A05-20C, Version 1.1.

Source

Institute for Quality and Efficiency in Health Care: Executive Summaries [Internet]. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2005-.
2011 May 30.

Excerpt

The aim of this research is to: assess the benefit of treatment with bupropion, mirtazapine or reboxetine in treating the acute phase of depression, in maintenance therapy (relapse prevention), and in recurrence prevention compared to: treatment with placebo; each other; treatment with other antidepressants; in each case in adult patients with depression. The focus of the investigation was on patient-relevant outcomes.

© IQWiG (Institute for Quality and Efficiency in Health Care).

LinkOut - more resources

Full Text Sources

Other Literature Sources

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Health
    Loading ...
    Support Center